A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

NCT06942572 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Stargardt Disease
Stargardt Macular Degeneration
Stargardt Macular Dystrophy

Interventions

GENETIC: SB-007

Sponsor

Splice Bio